PMID- 24649319
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 2049-9450 (Print)
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Linking)
VI  - 2
IP  - 1
DP  - 2014 Jan
TI  - Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma 
      kinase rearrangement-positive lung adenocarcinoma: A case report.
PG  - 121-123
AB  - Non-small-cell lung cancer (NSCLC) is the most commonly diagnosed type of cancer 
      and is a leading cause of cancer-related mortality worldwide. Treatment is 
      currently focused on individualization according to the molecular profile of the 
      disease. Here we present the case of a 41-year-old patient who presented with 
      multiple pulmonary nodules, a left pleural effusion and an ovarian tumor. 
      Adenocarcinoma of the lung was diagnosed from pathological examination of the 
      pleural effusion and the surgically resected ovarian tumor, and chemotherapy was 
      initiated. Relapse was experienced following third-line chemotherapy with 
      pemetrexed and anaplastic lymphoma kinase (ALK)-positive adenocarcinoma was 
      diagnosed using a specimen from the resected ovarian tumor. Subsequently, 
      crizotinib therapy was initiated. Eight days later the patient developed severe 
      nausea and vomiting and esophagitis was diagnosed by gastrointestinal endoscopic 
      examination. Following the interruption of crizotinib treatment by treatment with 
      a proton pump inhibitor (PPI), crizotinib treatment was re-initiated and was 
      effective for a minimum of 6 months. Clinicians should be aware that treatment 
      with crizotinib may result in severe esophagitis.
FAU - Takakuwa, Osamu
AU  - Takakuwa O
AD  - Department of Medical Oncology and Immunology, Nagoya City University, Graduate 
      School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
FAU - Oguri, Tetsuya
AU  - Oguri T
AD  - Department of Medical Oncology and Immunology, Nagoya City University, Graduate 
      School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
FAU - Yokoyama, Midori
AU  - Yokoyama M
AD  - Department of Medical Oncology and Immunology, Nagoya City University, Graduate 
      School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
FAU - Hijikata, Hisatoshi
AU  - Hijikata H
AD  - Department of Medical Oncology and Immunology, Nagoya City University, Graduate 
      School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
FAU - Uemura, Takehiro
AU  - Uemura T
AD  - Department of Medical Oncology and Immunology, Nagoya City University, Graduate 
      School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
FAU - Ohkubo, Hirotsugu
AU  - Ohkubo H
AD  - Department of Medical Oncology and Immunology, Nagoya City University, Graduate 
      School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
FAU - Maeno, Ken
AU  - Maeno K
AD  - Department of Medical Oncology and Immunology, Nagoya City University, Graduate 
      School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
FAU - Niimi, Akio
AU  - Niimi A
AD  - Department of Medical Oncology and Immunology, Nagoya City University, Graduate 
      School of Medical Sciences, Nagoya, Aichi 467-8601, Japan.
LA  - eng
PT  - Journal Article
DEP - 20130920
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC3916192
OTO - NOTNLM
OT  - anaplastic lymphoma kinase
OT  - crizotinib
OT  - non-small-cell lung cancer
OT  - pemetrexed
EDAT- 2014/03/22 06:00
MHDA- 2014/03/22 06:01
PMCR- 2013/09/20
CRDT- 2014/03/21 06:00
PHST- 2013/04/24 00:00 [received]
PHST- 2013/09/09 00:00 [accepted]
PHST- 2014/03/21 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2014/03/22 06:01 [medline]
PHST- 2013/09/20 00:00 [pmc-release]
AID - mco-02-01-0121 [pii]
AID - 10.3892/mco.2013.188 [doi]
PST - ppublish
SO  - Mol Clin Oncol. 2014 Jan;2(1):121-123. doi: 10.3892/mco.2013.188. Epub 2013 Sep 
      20.